This content is available for reuse with permission. If you are interested in reusing this content, please email newsroom@davita.com.
At a Glance While a kidney transplant is the most clinically- and cost-effective treatment for end stage kidney disease (ESKD), systemic barriers and social determinants of health frequently leave underserved communities behind. Accelerating the path to transplant can help close persistent gaps in chronic disease management while also reducing the time patients spend on dialysis. […]
As DaVita expands access to Expanded hemodialysis (HD), some patients who have recently started the treatment have shared positive personal experiences, including changes in how they feel day to day. These individual stories reflect patients’ perspectives and experiences and should not be interpreted as evidence of clinical outcomes for all patients. Real-World Patient Experiences The […]
DaVita will also continue hemodiafiltration (HDF) pilots to advance a comprehensive approach to middle molecule clearance. In the ongoing pursuit of improved outcomes in kidney care, few targets have been as stubborn as the middle molecule gap. When middle molecules — larger uremic toxins that are not effectively cleared during standard high-flux dialysis — accumulate, […]
By: Michael Moustakakis, MD, Group Medical Director for DaVita Extreme heat waves trigger standard public health advice everywhere: Drink plenty of water. For the general public, it’s a vital strategy to stay healthy and avoid heatstroke. But for the approximately 550,000 Americans living with end stage kidney disease (ESKD) and managing life on dialysis, this […]
With more than 90,000 people in the U.S. on the national transplant waitlist, the demand for life-saving organs far outpaces the supply. Living donation offers a strong pathway to addressing this public health challenge, and supporting a larger potential donor pool requires providing clarity on perceived barriers in the process. Angela Laino, a DaVita social […]